Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

GSK, Vernalis in $200 million oncology research deal
September 2009
SHARING OPTIONS:

LONDON— GlaxoSmithKline PLC and Vernalis PLC, a development-stage pharmaceutical company specializing in de novo fragment and structure-based drug discovery and preclinical and clinical development, announced in August that they have entered into an exclusive collaboration, option and license agreement relating to a Vernalis research program against an undisclosed oncology target.
 
The deal is structured as a risk-sharing agreement, with Vernalis responsible for drug discovery activities and GSK for preclinical development. Vernalis will receive $6 million up front, potential milestone payments in excess of $200 million and up to double-digit royalties based on worldwide sales of an oncology product.
 
Further milestones and royalties could be earned should products against the target be developed for indications outside of oncology. Upon IND filing, GSK will have the option to license all collaboration compounds and be responsible for all future development and commercialization activities.
 

Back



PAGE UTILITIES


CONTACT US
DDNEWS
1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.